TC 6987

Drug Profile

TC 6987

Alternative Names: TC-6987

Latest Information Update: 09 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Targacept
  • Class Antiasthmatics; Antihyperglycaemics; Small molecules
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Type 2 diabetes mellitus

Most Recent Events

  • 02 Aug 2016 Catalyst Biosciences enters into a definitive agreement with Attenua for the divestiture of its neuronal nicotinic receptors
  • 31 Dec 2012 Discontinued - Phase-II for Asthma in USA (PO)
  • 10 Apr 2012 Revised top-line efficacy data from a Phase-II trial in Asthma released by Targacept
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top